---
layout: default
title: Ramucirumab
parent: 僅模型預測 (L5)
nav_order: 534
evidence_level: L5
indication_count: 10
---

# Ramucirumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ramucirumab: From Undocumented Original Indication to Uterine Ligament Adenocarcinoma

## One-Sentence Summary

Ramucirumab is described in this evidence pack's rationale text as a fully human anti-VEGFR2 IgG1 monoclonal antibody that blocks VEGF-A/C/D binding to inhibit tumour angiogenesis; however, its official original indication and MOA fields are flagged as data gaps (DG001, DG002), so the drug's approved use cannot be confirmed here. The TxGNN model's top prediction is **Uterine Ligament Adenocarcinoma**, but this label is likely a rare/broad ontology artifact rather than a standard clinical diagnosis, and **0 clinical trials** and **0 publications** currently support this specific link.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented — no license text available (drug not marketed locally); see DG002 |
| Predicted New Indication | Uterine Ligament Adenocarcinoma |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for ramucirumab is not available in this evidence pack (DG002, High severity). Based on the repurposing rationale attached to other candidates in this same prediction set, ramucirumab is characterized as a fully human anti-VEGFR2 IgG1 monoclonal antibody that blocks VEGF-A/C/D–VEGFR2 binding to inhibit tumour angiogenesis — consistent with its known class as an anti-angiogenic targeted therapy in oncology.

The top-ranked predicted indication, "uterine ligament adenocarcinoma," is flagged in its own rationale as **not a standard clinical diagnostic entity** — it is more likely a rare or broadly-defined tumour label from the disease ontology underlying TxGNN's knowledge graph, produced by link prediction rather than a curated clinical match. The mechanistic argument (anti-angiogenic activity applicable to vascularization-dependent solid tumours) can still be applied in general terms, but the clinical correspondence of this specific entity is uncertain and should be verified against the source ontology before further evaluation.

Other candidates in the same top-10 set (notably rank 2, endocervical carcinoma) carry a stronger class-effect argument: bevacizumab, another anti-VEGFR2/VEGF-A pathway agent, demonstrated a survival benefit in cervical cancer in the Phase III GOG-240 trial. This supports biological plausibility for anti-angiogenic agents in gynecologic malignancies generally, though it is cross-drug extrapolation, not direct evidence for ramucirumab, and no ramucirumab trials in any of these ten indications were found via ClinicalTrials.gov, ICTRP, or PubMed searches.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Saudi Arabia Market Information

Ramucirumab is not currently marketed in Saudi Arabia — 0 authorizations are on record, and no license-level indication text is available.

---

## Cytotoxicity

Ramucirumab targets vascularized solid tumours (all ten predicted indications in this pack are gynecologic malignancies) and is characterized in the accompanying rationale text as a monoclonal antibody — this places it in the antineoplastic/targeted-therapy category.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (anti-VEGFR2 monoclonal antibody, anti-angiogenic) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All ten predicted indications are TxGNN model output only (L5), with zero supporting clinical trials or literature across every disease queried. The top-ranked entity itself is flagged as a likely non-standard/ontology-derived label, undermining confidence in the highest-scoring prediction specifically.

**To proceed, the following is needed:**
- TFDA/official package insert warnings and contraindications (DG001, Blocking — required before any S1 safety screening can proceed)
- Confirmed mechanism of action from DrugBank API (DG002)
- Confirmation of what clinical entity "uterine ligament adenocarcinoma" maps to in the source disease ontology
- If pursuing this line, prioritize rank 2 (endocervical carcinoma) for closer review given its class-effect precedent (bevacizumab/GOG-240) over the ontologically ambiguous rank 1 candidate
- Direct ramucirumab clinical evidence in gynecologic cancers, none of which currently exists per this search
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

